Prognostic Role of the C-PLAN Index in Metastatic Melanoma: A Two-Center Retrospective Study
- 1Medical Oncology Department, Kayseri City Hospital, 38080 Kayseri, Türkiye
- 2Medical Oncology Department, Erciyes University Medical School, 38030 Kayseri, Türkiye
Abstract
Background: The C-PLAN index is a composite prognostic tool incorporating clinical, inflammatory, nutritional, and biochemical parameters. Its prognostic role in metastatic melanoma remains insufficiently investigated. This study aimed to evaluate the association between the C-PLAN index and survival outcomes in patients with metastatic melanoma. Methods: This retrospective two-center study included 130 patients with metastatic melanoma treated at Erciyes University and Erzurum City Hospital between January 2012 and September 2023. The C-PLAN index was calculated using five parameters: Eastern Cooperative Oncology Group performance status, C-reactive protein, lactate dehydrogenase, serum albumin, and derived neutrophil-to-lymphocyte ratio (dNLR). Patients were classified into C-PLAN score groups of 0–1 and ≥2. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan–Meier analysis and Cox proportional hazards regression. Results: Among the 130 patients, 48 (36.9%) had a C-PLAN score of 0–1 and 82 (63.1%) had a score of ≥2. During follow-up, 76 patients experienced a PFS event, and 94 died. Median PFS was longer in the C-PLAN 0–1 group than in the ≥2 group (30.27 vs. 9.17 months; log-rank p < 0.001). Median OS was also longer in the C-PLAN 0–1 group (82.93 vs. 29.70 months; log-rank p < 0.001). In the multivariable Cox regression analysis for PFS, a C-PLAN score of ≥2 was associated with a higher hazard of progression or death (HR, 3.193; 95% CI, 1.774–5.746; p < 0.001). A higher number of metastatic sites, BMI category, mitotic activity, lymphatic invasion, and BRAF status were also independently associated with PFS. In the multivariable Cox regression analysis for OS, a C-PLAN score of ≥2 (HR, 3.227; 95% CI, 1.910–5.455; p < 0.001) and a higher number of metastatic sites (HR, 2.453; 95% CI, 1.538–3.912; p < 0.001) were independently associated with a higher hazard of death. Conclusions: In this retrospective two-center cohort, a C-PLAN score of ≥2 was associated with shorter PFS and OS. These findings should be interpreted as exploratory and support further investigation of C-PLAN as a prognostic index in melanoma. Validation in larger, contemporary, and independent cohorts is required before its clinical utility can be established.
Related
- Utility of Chemotherapy for Metastatic Melanoma in the Contemporary Era and Experience with Modified Vinblastine–Cisplatin–Temozolomide at a Tertiary Care Center
- Association of preoperative D-dimer-to-albumin ratio and prognostic nutritional index with aseptic wound complications and periprosthetic joint infection after primary total knee arthroplasty: a single-center retrospective cohort study
- A 20-Year Real-World Benchmark of Metastatic Uveal Melanoma Outcomes in a Tebentafusp-Inaccessible Setting: A Comprehensive Cancer Center Study
- Prognostic Value of Metabolic–Muscle Reserve Index in HR+/HER2− Metastatic Breast Cancer Treated with CDK4/6 Inhibitors
- Clinical utility of combining the C-reactive protein-to-albumin ratio and systemic immune-inflammation index for prognostic assessment in metastatic renal cell carcinoma
BibTeX
@article{bugday2026prognostic,
title = {{Prognostic Role of the C-PLAN Index in Metastatic Melanoma: A Two-Center Retrospective Study}},
author = {İrfan Buğday and Safiye Selcen Vicdanlı and Mevlüde İnanç and Metin Özkan and Oktay Bozkurt},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15218261},
url = {https://www.mdpi.com/2077-0383/15/21/8261},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Prognostic Role of the C-PLAN Index in Metastatic Melanoma: A Two-Center Retrospective Study
AU - İrfan Buğday
AU - Safiye Selcen Vicdanlı
AU - Mevlüde İnanç
AU - Metin Özkan
AU - Oktay Bozkurt
PY - 2026
DA - 2026/10/23
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15218261
UR - https://www.mdpi.com/2077-0383/15/21/8261
AB - Background: The C-PLAN index is a composite prognostic tool incorporating clinical, inflammatory, nutritional, and biochemical parameters. Its prognostic role in metastatic melanoma remains insufficiently investigated. This study aimed to evaluate the association between the C-PLAN index and survival outcomes in patients with metastatic melanoma. Methods: This retrospective two-center study included 130 patients with metastatic melanoma treated at Erciyes University and Erzurum City Hospital between January 2012 and September 2023. The C-PLAN index was calculated using five parameters: Eastern Cooperative Oncology Group performance status, C-reactive protein, lactate dehydrogenase, serum albumin, and derived neutrophil-to-lymphocyte ratio (dNLR). Patients were classified into C-PLAN score groups of 0–1 and ≥2. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan–Meier analysis and Cox proportional hazards regression. Results: Among the 130 patients, 48 (36.9%) had a C-PLAN score of 0–1 and 82 (63.1%) had a score of ≥2. During follow-up, 76 patients experienced a PFS event, and 94 died. Median PFS was longer in the C-PLAN 0–1 group than in the ≥2 group (30.27 vs. 9.17 months; log-rank p < 0.001). Median OS was also longer in the C-PLAN 0–1 group (82.93 vs. 29.70 months; log-rank p < 0.001). In the multivariable Cox regression analysis for PFS, a C-PLAN score of ≥2 was associated with a higher hazard of progression or death (HR, 3.193; 95% CI, 1.774–5.746; p < 0.001). A higher number of metastatic sites, BMI category, mitotic activity, lymphatic invasion, and BRAF status were also independently associated with PFS. In the multivariable Cox regression analysis for OS, a C-PLAN score of ≥2 (HR, 3.227; 95% CI, 1.910–5.455; p < 0.001) and a higher number of metastatic sites (HR, 2.453; 95% CI, 1.538–3.912; p < 0.001) were independently associated with a higher hazard of death. Conclusions: In this retrospective two-center cohort, a C-PLAN score of ≥2 was associated with shorter PFS and OS. These findings should be interpreted as exploratory and support further investigation of C-PLAN as a prognostic index in melanoma. Validation in larger, contemporary, and independent cohorts is required before its clinical utility can be established.
SN - 2077-0383
ER -